We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-4.71%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$477M
AUM Growth
-$7.14M
Cap. Flow
+$18.1M
Cap. Flow %
3.8%
Top 10 Hldgs %
55.56%
Holding
40
New
12
Increased
10
Reduced
5
Closed
10

Top Buys

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$15.6M
2
RPTX
Repare Therapeutics
RPTX
+$14.3M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$12.8M
4
DYN icon
Dyne Therapeutics
DYN
+$12.6M
5
KURA icon
Kura Oncology
KURA
+$12.4M

Top Sells

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$29.4M
2
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$20.4M
3
LNTH icon
Lantheus
LNTH
+$13.9M
4
BIIB icon
Biogen
BIIB
+$12.9M
5
XENT
Intersect ENT, Inc
XENT
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 91.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
1
MacroGenics
MGNX
$235M
$37M 7.77%
1,378,495
+28,495
+2% +$834K
RCKT icon
2
Rocket Pharmaceuticals
RCKT
$340M
$36.2M 7.59%
817,040
+57,040
+8% +$2.48M
ARNA
3
DELISTED
Arena Pharmaceuticals Inc
ARNA
$34.5M 7.23%
505,670
+129,800
+35% +$8.46M
UTHR icon
4
United Therapeutics
UTHR
$25.8B
$31.6M 6.64%
176,406
+20,000
+13% +$3.81M
PODD icon
5
Insulet
PODD
$11.5B
$28.7M 6.02%
104,600
+15,000
+17% +$4.08M
EXEL icon
6
Exelixis
EXEL
$13.3B
$25.4M 5.33%
1,394,107
+193,007
+16% +$4.5M
COLL icon
7
Collegium Pharmaceutical
COLL
$1.15B
$20.4M 4.27%
861,410
– –
KDMN
8
DELISTED
Kadmon Holdings, Inc.
KDMN
$18.7M 3.92%
4,830,000
+75,000
+2% +$291K
NTLA icon
9
CALL
Intellia Therapeutics
NTLA
$1.49B
$16.2M 3.4%
+100,000
New +$7.79M
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$16.2M 3.39%
100,000
-35,000
-26% -$5.62M
TVTX icon
11
Travere Therapeutics
TVTX
$5.2B
$15.8M 3.32%
1,084,300
+490,588
+83% +$9.68M
FOLD
12
DELISTED
Amicus Therapeutics
FOLD
$15.4M 3.24%
+1,600,000
New +$15.6M
SAGE
13
DELISTED
Sage Therapeutics
SAGE
$14.2M 2.98%
250,000
-132,085
-35% -$9.34M
DYN icon
14
Dyne Therapeutics
DYN
$4.7B
$14.2M 2.97%
+672,559
New +$12.6M
RPTX
15
DELISTED
Repare Therapeutics
RPTX
$13.6M 2.85%
+436,089
New +$14.3M
KYNB
16
CALL
Kyntra Bio
KYNB
$27.2M
$13.3M 2.79%
+20,000
New +$11.5M
OCUL icon
17
Ocular Therapeutix
OCUL
$1.79B
$13M 2.74%
919,887
-87,125
-9% -$1.32M
XENT
18
DELISTED
Intersect ENT, Inc
XENT
$12M 2.51%
700,000
-632,773
-47% -$11.8M
PBYI icon
19
Puma Biotechnology
PBYI
$404M
$11.9M 2.5%
1,300,000
– –
BIIB icon
20
Biogen
BIIB
$30B
$11.3M 2.36%
32,500
-42,500
-57% -$12.9M
DNTH icon
21
Dianthus Therapeutics
DNTH
$5.84B
$10.9M 2.28%
+69,444
New +$12.8M
KURA icon
22
Kura Oncology
KURA
$800M
$10.4M 2.19%
+500,000
New +$12.4M
ANAB icon
23
AnaptysBio
ANAB
$1.58B
$10.4M 2.18%
+400,051
New +$9.59M
OLMA icon
24
Olema Pharmaceuticals
OLMA
$1B
$9.21M 1.93%
+329,086
New +$9.36M
TCDA
25
DELISTED
Tricida, Inc. Common Stock
TCDA
$8.53M 1.79%
1,974,000
+1,624,400
+465% +$7.74M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2021 Portfolio in Review

As of Q2 2021, Great Point Partners held 40 positions worth $477M, down 1.5% from $484M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Great Point Partners deployed $18.1M of net new capital in Q2 2021, opening 12 new positions and adding to 10 existing holdings. Its largest new stake was Amicus Therapeutics: 1,600,000 shares worth $15.4M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier.

On the sell side, the largest reduction was Biogen, an estimated $12.9M trimmed.

  • Great Point Partners's largest Q2 2021 buy was Amicus Therapeutics: 1,600,000 shares worth $15.4M.
  • Great Point Partners added most to Travere Therapeutics in Q2 2021, an estimated $9.68M increase.
  • Great Point Partners's biggest Q2 2021 reduction was Biogen, cutting an estimated $12.9M.
  • Great Point Partners fully exited Iovance Biotherapeutics in Q2 2021, selling an estimated $29.4M.
  • Great Point Partners's ten largest holdings make up 56% of its $477M portfolio in Q2 2021.
  • Great Point Partners opened 12 new positions and closed 10 in Q2 2021.
  • Great Point Partners's portfolio value fell 1.5% quarter-over-quarter to $477M.

Based on Great Point Partners's 13F filing for Q2 2021, filed 16 Aug 2021.